Discontinued — last reported Q1 '26
Business Segments · Restructuring Charges
Oncology & Multispecialty — Restructuring Charges
This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ2 2023
Last reportedQ1 2026
Rolls up toRestructuring Charges
How to read this metric
High charges indicate significant organizational transformation, which may lead to future margin improvements but creates short-term earnings pressure.
Detailed definition
This metric aggregates the total costs associated with formal restructuring programs designed to streamline operations,...
Peer comparison
Similar to restructuring charges reported by other diversified healthcare companies during periods of operational transformation.
Metric ID:
mck_segment_oncology_multispecialty_restructuring_chargesHistorical Data
9 periods
| Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $2.25M | $2.25M | $2.25M | $2.25M | $1.00M | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -55.6% | -100.0% | — | — | — |
| YoY Change | — | — | — | — | -55.6% | — | — | -100.0% | — |
Range$0.00 – $2.25M
CAGR-100.0%
Avg YoY Growth-77.8%
Median YoY Growth-77.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — restructuring charges?
- McKesson (MCK) reported oncology & multispecialty — restructuring charges of $0.00 in Q1 2026.
- What does oncology & multispecialty — restructuring charges mean?
- Total costs incurred for restructuring activities within the Oncology and Multispecialty segment.